These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 28735965)

  • 1. Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.
    Launay O; Lewis DJM; Anemona A; Loulergue P; Leahy J; Sciré AS; Maugard A; Marchetti E; Zancan S; Huo Z; Rondini S; Marhaba R; Finco O; Martin LB; Auerbach J; Cohen D; Saul A; Gerke C; Podda A
    EBioMedicine; 2017 Aug; 22():164-172. PubMed ID: 28735965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Booster Vaccination With GVGH
    Launay O; Ndiaye AGW; Conti V; Loulergue P; Sciré AS; Landre AM; Ferruzzi P; Nedjaai N; Schütte LD; Auerbach J; Marchetti E; Saul A; Martin LB; Podda A
    Front Immunol; 2019; 10():335. PubMed ID: 30906291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against
    Obiero CW; Ndiaye AGW; Sciré AS; Kaunyangi BM; Marchetti E; Gone AM; Schütte LD; Riccucci D; Auerbach J; Saul A; Martin LB; Bejon P; Njuguna P; Podda A
    Front Immunol; 2017; 8():1884. PubMed ID: 29375556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies Elicited by the
    Micoli F; Rossi O; Conti V; Launay O; Sciré AS; Aruta MG; Nakakana UN; Marchetti E; Rappuoli R; Saul A; Martin LB; Necchi F; Podda A
    Front Immunol; 2021; 12():671325. PubMed ID: 34017343
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB.
    Gerke C; Colucci AM; Giannelli C; Sanzone S; Vitali CG; Sollai L; Rossi O; Martin LB; Auerbach J; Di Cioccio V; Saul A
    PLoS One; 2015; 10(8):e0134478. PubMed ID: 26248044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach.
    Necchi F; Carducci M; Pisoni I; Rossi O; Saul A; Rondini S
    J Immunol Methods; 2019 Aug; 471():11-17. PubMed ID: 31039338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children.
    Passwell JH; Ashkenazi S; Banet-Levi Y; Ramon-Saraf R; Farzam N; Lerner-Geva L; Even-Nir H; Yerushalmi B; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Vaccine; 2010 Mar; 28(10):2231-2235. PubMed ID: 20056180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-mediated serum bactericidal activity of antibodies elicited by the
    Kapulu MC; Nakakana U; Sciré AS; Sarakinou E; Conti V; Rossi O; Acquaviva A; Necchi F; Obiero CW; Martin LB; Bejon P; Njuguna P; Micoli F; Podda A
    Front Immunol; 2022; 13():971866. PubMed ID: 36203568
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.
    Leroux-Roels I; Maes C; Mancini F; Jacobs B; Sarakinou E; Alhatemi A; Joye J; Grappi S; Cilio GL; Serry-Bangura A; Vitali CG; Ferruzzi P; Marchetti E; Necchi F; Rappuoli R; De Ryck I; Auerbach J; Colucci AM; Rossi O; Conti V; Scorza FB; Arora AK; Micoli F; Podda A; Nakakana UN;
    J Infect Dis; 2024 Oct; 230(4):e971-e984. PubMed ID: 38853614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and immunogenicity of the
    Frenck RW; Conti V; Ferruzzi P; Ndiaye AGW; Parker S; McNeal MM; Dickey M; Granada JP; Cilio GL; De Ryck I; Necchi F; Suvarnapunya AE; Rossi O; Acquaviva A; Chandrasekaran L; Clarkson KA; Auerbach J; Marchetti E; Kaminski RW; Micoli F; Rappuoli R; Saul A; Martin LB; Podda A
    EClinicalMedicine; 2021 Sep; 39():101076. PubMed ID: 34430837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA).
    Mancini F; Gasperini G; Rossi O; Aruta MG; Raso MM; Alfini R; Biagini M; Necchi F; Micoli F
    Sci Rep; 2021 Jan; 11(1):906. PubMed ID: 33441861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of WRSS1, a
    Raqib R; Sarker P; Zaman K; Alam NH; Wierzba TF; Maier N; Talukder K; Baqui AH; Suvarnapunya AE; Qadri F; Walker RI; Fix A; Venkatesan MM
    Hum Vaccin Immunother; 2019; 15(6):1326-1337. PubMed ID: 30794051
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.
    Pitisuttithum P; Islam D; Chamnanchanunt S; Ruamsap N; Khantapura P; Kaewkungwal J; Kittitrakul C; Luvira V; Dhitavat J; Venkatesan MM; Mason CJ; Bodhidatta L
    Clin Vaccine Immunol; 2016 Jul; 23(7):564-75. PubMed ID: 27146000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
    Orr N; Katz DE; Atsmon J; Radu P; Yavzori M; Halperin T; Sela T; Kayouf R; Klein Z; Ambar R; Cohen D; Wolf MK; Venkatesan MM; Hale TL
    Infect Immun; 2005 Dec; 73(12):8027-32. PubMed ID: 16299296
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.